EP4125977A4 - CROSS-SPECIES COMPATIBLE ADENO-ASSOCIATED VIRUS COMPOSITIONS AND METHODS OF USE THEREOF - Google Patents

CROSS-SPECIES COMPATIBLE ADENO-ASSOCIATED VIRUS COMPOSITIONS AND METHODS OF USE THEREOF Download PDF

Info

Publication number
EP4125977A4
EP4125977A4 EP21800135.2A EP21800135A EP4125977A4 EP 4125977 A4 EP4125977 A4 EP 4125977A4 EP 21800135 A EP21800135 A EP 21800135A EP 4125977 A4 EP4125977 A4 EP 4125977A4
Authority
EP
European Patent Office
Prior art keywords
adeno
methods
cross
associated virus
species compatible
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21800135.2A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4125977A2 (en
Inventor
Aravind Asokan
Trevor GONZALEZ
Lawrence Patrick HAVLIK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of EP4125977A2 publication Critical patent/EP4125977A2/en
Publication of EP4125977A4 publication Critical patent/EP4125977A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP21800135.2A 2020-05-05 2021-05-05 CROSS-SPECIES COMPATIBLE ADENO-ASSOCIATED VIRUS COMPOSITIONS AND METHODS OF USE THEREOF Pending EP4125977A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063020062P 2020-05-05 2020-05-05
PCT/US2021/030937 WO2021226267A2 (en) 2020-05-05 2021-05-05 Cross-species compatible adeno-associated virus compositions and methods of use thereof

Publications (2)

Publication Number Publication Date
EP4125977A2 EP4125977A2 (en) 2023-02-08
EP4125977A4 true EP4125977A4 (en) 2024-09-25

Family

ID=78468375

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21800135.2A Pending EP4125977A4 (en) 2020-05-05 2021-05-05 CROSS-SPECIES COMPATIBLE ADENO-ASSOCIATED VIRUS COMPOSITIONS AND METHODS OF USE THEREOF

Country Status (13)

Country Link
US (3) US12577586B2 (enExample)
EP (1) EP4125977A4 (enExample)
JP (1) JP7756439B2 (enExample)
KR (1) KR20230029616A (enExample)
CN (1) CN116096377B (enExample)
AR (1) AR122013A1 (enExample)
AU (1) AU2021268946A1 (enExample)
BR (1) BR112022022644A2 (enExample)
CA (1) CA3177869A1 (enExample)
IL (1) IL297577A (enExample)
MX (1) MX2022013963A (enExample)
TW (1) TWI910162B (enExample)
WO (1) WO2021226267A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI910162B (zh) * 2020-05-05 2026-01-01 美國公爵大學 跨物種相容腺相關病毒組合物及其使用方法
KR20240095539A (ko) 2021-10-08 2024-06-25 디노 테라퓨틱스, 인코포레이티드 캡시드 변이체 및 이의 사용 방법
WO2024044725A2 (en) * 2022-08-24 2024-02-29 Regenxbio Inc. Recombinant adeno-associated viruses and uses thereof
WO2024168089A2 (en) * 2023-02-07 2024-08-15 Duke University Compositions comprising aavs and methods for treating gastrointestinal diseases
US20240261438A1 (en) * 2023-02-08 2024-08-08 Ginkgo Bioworks, Inc. Gene therapy for angelman syndrome
JP2026509271A (ja) 2023-03-10 2026-03-17 ダイノ セラピューティクス，インコーポレーテッド カプシドポリペプチドおよびその使用方法
EP4689139A1 (en) * 2023-03-31 2026-02-11 Duke University Compositions comprising brain-tropic aavs and methods of use thereof
KR20260082361A (ko) 2023-08-31 2026-06-04 디노 테라퓨틱스, 인코포레이티드 캡시드 폴리펩타이드 및 이의 사용 방법
TW202545971A (zh) 2024-02-08 2025-12-01 美商戴諾治療公司 殼體多肽及其使用方法
WO2025250454A1 (en) * 2024-05-28 2025-12-04 University Of Rochester Adeno-associated viruses evolved to specifically target human glial progenitor cells in vivo
WO2026064442A2 (en) 2024-09-18 2026-03-26 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
WO2026122963A1 (en) 2024-12-06 2026-06-11 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160017295A1 (en) * 2013-05-31 2016-01-21 The Regents Of The University Of California Adeno-associated virus variants and methods of use thereof
US20170067908A1 (en) * 2014-04-25 2017-03-09 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
US20170130245A1 (en) * 2014-06-09 2017-05-11 Voyager Therapeutics, Inc. Chimeric capsids
US20190048041A1 (en) * 2015-09-28 2019-02-14 The University Of North Carlolina At Chapel Hill Methods and compositions for antibody-evading virus vectors
WO2019195444A1 (en) * 2018-04-03 2019-10-10 Stridebio, Inc. Antibody-evading virus vectors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
US7314912B1 (en) 1999-06-21 2008-01-01 Medigene Aktiengesellschaft AAv scleroprotein, production and use thereof
US7465583B2 (en) 2000-06-01 2008-12-16 The University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
CN101528916B (zh) * 2006-04-28 2013-09-04 宾夕法尼亚大学托管会 规模可调的aav生产方法
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
CA2826273C (en) 2011-02-10 2021-11-02 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
EP3470523A1 (en) 2012-05-09 2019-04-17 Oregon Health & Science University Adeno associated virus plasmids and vectors
EP3583220A4 (en) * 2017-02-15 2021-07-07 The University of North Carolina at Chapel Hill PROCEDURES AND COMPOSITIONS FOR GENERAL TRANSFER IN THE VASCULAR SYSTEM
JP2020510424A (ja) 2017-02-28 2020-04-09 アドヴェラム バイオテクノロジーズ， インコーポレイテッド 改変ａａｖカプシドおよびその使用
GB2574561A (en) 2017-03-14 2019-12-11 Univ California Engineering CRISPR CAS9 immune stealth
WO2018170310A1 (en) 2017-03-15 2018-09-20 The University Of North Carolina At Chapel Hill Polyploid adeno-associated virus vectors and methods of making and using the same
US10550405B2 (en) 2017-03-15 2020-02-04 The University Of North Carolina At Chapel Hill Rational polyploid adeno-associated virus vectors and methods of making and using the same
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
MX2020010465A (es) * 2018-04-03 2021-01-08 Vectores de virus para direccionamiento a tejidos oftalmicos.
WO2019222444A2 (en) 2018-05-16 2019-11-21 Voyager Therapeutics, Inc. Directed evolution
EP3860659A1 (en) * 2018-10-01 2021-08-11 The Trustees of the University of Pennsylvania Compositions useful for treating gm1 gangliosidosis
CN113727992A (zh) 2019-03-21 2021-11-30 斯特里迪比奥公司 重组腺相关病毒载体
TWI910162B (zh) 2020-05-05 2026-01-01 美國公爵大學 跨物種相容腺相關病毒組合物及其使用方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160017295A1 (en) * 2013-05-31 2016-01-21 The Regents Of The University Of California Adeno-associated virus variants and methods of use thereof
US20170067908A1 (en) * 2014-04-25 2017-03-09 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
US20170130245A1 (en) * 2014-06-09 2017-05-11 Voyager Therapeutics, Inc. Chimeric capsids
US20190048041A1 (en) * 2015-09-28 2019-02-14 The University Of North Carlolina At Chapel Hill Methods and compositions for antibody-evading virus vectors
WO2019195444A1 (en) * 2018-04-03 2019-10-10 Stridebio, Inc. Antibody-evading virus vectors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HILDEGARD BÜNING: "Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors - ScienceDirect", MOLECULAR THERAPY- METHODS & CLINICAL DEVELOPMENT, vol. 12, 1 March 2019 (2019-03-01), GB, pages 248 - 265, XP093168492, ISSN: 2329-0501, Retrieved from the Internet <URL:https://www.sciencedirect.com/science/article/pii/S2329050119300117?via=ihub> DOI: 10.1016/j.omtm.2019.01.008 *
JASON L PICCONI ET AL: "Kidney-specific expression of GFP by in-utero delivery of pseudotyped adeno-associated virus 9", MOLECULAR THERAPY- METHODS & CLINICAL DEVELOPMENT, vol. 1, 1 January 2014 (2014-01-01), GB, pages 14014, XP055765300, ISSN: 2329-0501, DOI: 10.1038/mtm.2014.14 *
ROBERT D DAYTON ET AL: "The advent of AAV9 expands applications for brain and spinal cord gene delivery", EXPERT OPINION ON BIOLOGICAL THERAPY, vol. 12, no. 6, 15 June 2012 (2012-06-15), pages 757 - 766, XP055279735, ISSN: 1471-2598, DOI: 10.1517/14712598.2012.681463 *

Also Published As

Publication number Publication date
IL297577A (en) 2022-12-01
JP2023524291A (ja) 2023-06-09
MX2022013963A (es) 2023-02-22
TW202208631A (zh) 2022-03-01
AR122013A1 (es) 2022-08-03
EP4125977A2 (en) 2023-02-08
US12146151B2 (en) 2024-11-19
US20230151389A1 (en) 2023-05-18
CN116096377A (zh) 2023-05-09
CA3177869A1 (en) 2021-11-11
KR20230029616A (ko) 2023-03-03
US12577586B2 (en) 2026-03-17
US12037598B2 (en) 2024-07-16
US20240076695A1 (en) 2024-03-07
US20240067988A1 (en) 2024-02-29
WO2021226267A3 (en) 2021-12-16
BR112022022644A2 (pt) 2023-01-17
WO2021226267A2 (en) 2021-11-11
JP7756439B2 (ja) 2025-10-20
AU2021268946A1 (en) 2022-12-01
CN116096377B (zh) 2026-01-02
TWI910162B (zh) 2026-01-01

Similar Documents

Publication Publication Date Title
EP3959318A4 (en) OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE
EP3840730A4 (en) COMPOSITIONS FOR DELIVERY OF THERAPEUTICS AND METHOD OF USE AND MANUFACTURING THEREOF
EP3717636A4 (en) ADENO-ASSOCIATED VIRUS VARIANTS CAPSIDS AND USE TO INHIBIT ANGIOGENESIS
EP3684423A4 (en) VARIANT CAPSID WITH ADENO-ASSOCIATED VIRUS AND METHOD OF USE THEREOF
EP3917564A4 (en) ANTI-CLAUDIN-18 ANTIBODIES AND METHODS OF USE THEREOF
MA54952A (fr) Conjugués d&#39;il-2 et méthodes d&#39;utilisation de ceux-ci
EP3784697A4 (en) GMO AAV CAPSIDS WITH INCREASED TROPISM AND AAV VECTORS CONTAINING THE GMO CAPSIDS, AND METHODS FOR THEIR MANUFACTURE AND USE
EP3880688A4 (en) OLIGOSACCHARID PREPARATIONS AND COMPOSITIONS
MA44740A (fr) Variantes de capsides de virus adéno-associé et leurs procédés d&#39;utilisation
EP3843720A4 (en) COMPOSITIONS OF CXCR4 INHIBITORS AND METHODS OF MANUFACTURE AND USE
EP3893917A4 (en) IL-15 COMPOSITIONS AND METHODS OF USE THEREOF
EP4313002A4 (en) Polynucleotide compositions, associated formulations and methods of using the same
EP4308703A4 (en) Polynucleotide compositions, associated formulations and methods of using the same
EP3684369A4 (en) A33-ANTIBODY COMPOSITIONS AND METHOD OF USING THEREOF IN RADIOIMMUNOTHERAPY
EP3955902A4 (en) AEROSOLIZED COMPOSITIONS WITH MITOCHONDRIA AND METHODS OF USE
EP3634390A4 (en) ANTIMICROBIAL COMPOSITIONS OF CANNABINOIDS AND METHOD OF USING THEREOF
EP4004051A4 (en) IMMUNOMODULATORY ANTIBODIES AND METHODS OF USE THEREOF
EP4100539A4 (en) Adeno-associated variants, formulations and methods for pulmonary delivery
MA52200A (fr) Compositions de vaa, procédés de préparation et méthodes d&#39;utilisation
EP3743109A4 (en) MICA / B ANTIBODIES AND METHOD OF USE
EP4065145A4 (en) COMPOSITIONS FOR IMPROVING ATHLETE PERFORMANCE AND METHODS OF USE THEREOF
EP4423205A4 (en) POLISHING COMPOSITIONS AND METHODS OF USE THEREOF
EP4031520A4 (en) IMAGING AND THERAPEUTIC COMPOSITIONS
EP3817750A4 (en) CANNABIDIOL COMBINATION COMPOSITIONS
EP3930704A4 (en) COMPOSITIONS WITH CINNANIC ACID AND PROCESS FOR THE PREPARATION THEREOF

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221104

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40080218

Country of ref document: HK

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/86 20060101ALI20240412BHEP

Ipc: C12N 7/00 20060101ALI20240412BHEP

Ipc: C07K 14/005 20060101ALI20240412BHEP

Ipc: A61K 38/17 20060101ALI20240412BHEP

Ipc: A61K 31/7088 20060101ALI20240412BHEP

Ipc: A61K 35/76 20150101AFI20240412BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20240827

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/86 20060101ALI20240821BHEP

Ipc: C12N 7/00 20060101ALI20240821BHEP

Ipc: C07K 14/005 20060101ALI20240821BHEP

Ipc: A61K 38/17 20060101ALI20240821BHEP

Ipc: A61K 31/7088 20060101ALI20240821BHEP

Ipc: A61K 35/76 20150101AFI20240821BHEP